A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
NCT05409482 is an observational study sponsored by Meng Chao Hepatobiliary Hospital of Fujian Medical University. As of 18 Nov 2026, it is recruiting participants. It studies Hepatocellular Carcinoma. The registry lists an enrollment of 300 participants at 1 site in 1 country. The registry lists a start date of 20 Aug 2022 and a primary completion date of 1 Mar 2026. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05409482 |
| Status | Recruiting |
| Study type | Observational study |
| Lead sponsor | Meng Chao Hepatobiliary Hospital of Fujian Medical University |
| Enrollment | 300 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Hepatocellular Carcinoma |
| Start | 20 Aug 2022 |
| Primary completion | 1 Mar 2026 |
| Study completion | 1 Mar 2026 |
| Last update posted | 13 May 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Bo h Zhang
Zhongshan Hospital (Xiamen), Fudan University
Study Director - Cong r Wang
Quanzhou First Hospital
Study Director - Feng Lin
Ningde Mindong Hospital
Study Director - Fu q Wang
Xiamen Hospital of Traditional Chinese Medicine
Study Chair - Hui Zhang
Fujian Cancer Hospital
Study Director - Jia f Chen
Putian First Hospital
Study Director - Jian f Zhao
The Affiliated Hospital of Putian University
Study Director - Ling q Yan
Fuqing City Hospital
Study Director - Mao l Yan
Fujian Provincial Hospital
Study Director - Ning Huang
Union Hospital, Affiliated to Fujian Medical University
Study Director - Ping g Liu
Zhongshan Hospital Affiliated to Xiamen University
Study Director - Shao w Zhuang
Zhangzhou Hospital
Study Chair - Wen f Wu
Nanping Second Hospital
Study Director - Wen l Zeng
Longyan Second Hospital
Study Director - Wen x Xie
Fuding City Hospital
Study Director - Wu h Guo
Mengchao Hepatobiliary Hospital, Fujian Medical University
Study Director - Xiao j Zhang
The 900th Hospital of the Joint Logistics Support Force
Study Director - Yan m Zhou
The First Affiliated Hospital of Xiamen University
Study Director - Yi p Chen
First Affiliated Hospital of Fujian Medical University
Study Director - Yong yi Zeng
Mengchao Hepatobiliary Hospital, Fujian Medical University
Principal Investigator - Yong z Wang
Sanming Second Hospital
Study Director - Yu f Chen
Zhangzhou Hospital
Study Director - Zhi bo Zhang
First Affiliated Hospital of Fujian Medical University
Study Director - Zhu t Fang
Fujian Provincial Hospital
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mengchao Hepatobiliary Hospital, Fujian Medical University
Fuzhou, Fujian
Recruiting
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT05409482
Each answer restates registry values shown on this page.
What is NCT05409482?
NCT05409482 is an observational study sponsored by Meng Chao Hepatobiliary Hospital of Fujian Medical University. It studies Hepatocellular Carcinoma.
Is NCT05409482 recruiting?
As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.
Who leads NCT05409482?
The registry names Bo h Zhang (study director, Zhongshan Hospital (Xiamen), Fudan University), Cong r Wang (study director, Quanzhou First Hospital), Feng Lin (study director, Ningde Mindong Hospital) and 22 more officials as overall officials.
Where does NCT05409482 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.
When is NCT05409482 expected to complete?
The registry lists a primary completion date of 1 Mar 2026 and a study completion date of 1 Mar 2026. The sponsor last updated the record on 13 May 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.